AR046124A1 - Forma polimorfica de la n-[(r)-2,3-dihidroxipropoxi]-3,4 difluoro-2-(2-fluoro-4-iodofenilamino)benzamida; proceso de obtencion y composiciones farmaceuticas - Google Patents
Forma polimorfica de la n-[(r)-2,3-dihidroxipropoxi]-3,4 difluoro-2-(2-fluoro-4-iodofenilamino)benzamida; proceso de obtencion y composiciones farmaceuticasInfo
- Publication number
- AR046124A1 AR046124A1 ARP040103782A ARP040103782A AR046124A1 AR 046124 A1 AR046124 A1 AR 046124A1 AR P040103782 A ARP040103782 A AR P040103782A AR P040103782 A ARP040103782 A AR P040103782A AR 046124 A1 AR046124 A1 AR 046124A1
- Authority
- AR
- Argentina
- Prior art keywords
- difluoro
- fluoro
- pharmaceutical compositions
- polymorphic form
- iodofenilamino
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
Abstract
La presente se refiere a la forma polimórfica de la N-[(R)-2,3-dihidroxipropoxi]-3,4-difluoro-2-(2-fluoro-4-yodofenilamino)benzamida, proceso de obtención y composiciones farmacéuticas que los contienen. Reivindicación 1: Un polimorfo cristalina de la N-[(R)-2,3-dihidroxipropoxi]-3,4-difluoro-2-(2-fluoro-4-yodofenilamino)benzamida que muestra un patrón de difracción de polvo de rayos X que tiene picos característicos expresados en grados 2q a aproximadamente 4,6, 7,2, 14,6, 19,9, 23,2 y 26,5.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51298003P | 2003-10-21 | 2003-10-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR046124A1 true AR046124A1 (es) | 2005-11-23 |
Family
ID=34520067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040103782A AR046124A1 (es) | 2003-10-21 | 2004-10-19 | Forma polimorfica de la n-[(r)-2,3-dihidroxipropoxi]-3,4 difluoro-2-(2-fluoro-4-iodofenilamino)benzamida; proceso de obtencion y composiciones farmaceuticas |
Country Status (19)
Country | Link |
---|---|
US (1) | US7060856B2 (es) |
EP (1) | EP1682495A1 (es) |
JP (1) | JP2007509125A (es) |
KR (1) | KR101013932B1 (es) |
CN (1) | CN100594212C (es) |
AR (1) | AR046124A1 (es) |
AU (1) | AU2004283148A1 (es) |
BR (1) | BRPI0415710A (es) |
CA (1) | CA2542210A1 (es) |
CO (1) | CO5690569A2 (es) |
HK (1) | HK1093483A1 (es) |
IL (1) | IL174367A0 (es) |
MX (1) | MXPA06004363A (es) |
NO (1) | NO20062090L (es) |
NZ (1) | NZ546011A (es) |
RU (1) | RU2352558C2 (es) |
TW (1) | TW200524584A (es) |
WO (1) | WO2005040098A1 (es) |
ZA (1) | ZA200602250B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7429588B2 (en) * | 2001-03-27 | 2008-09-30 | Dainippon Sumitomo Pharma Co., Ltd. | Crystalline isoxazole derivative and medical preparation thereof |
WO2006061712A2 (en) * | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Use of mek inhibitors in treating abnormal cell growth |
WO2006134469A1 (en) * | 2005-06-14 | 2006-12-21 | Warner-Lambert Company Llc | Methods of preparing mek inhibitor |
WO2007042885A2 (en) * | 2005-10-07 | 2007-04-19 | Pfizer Products Inc. | Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2 |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
AU2009293019A1 (en) | 2008-09-19 | 2010-03-25 | Tandem Diabetes Care Inc. | Solute concentration measurement device and related methods |
US9250106B2 (en) | 2009-02-27 | 2016-02-02 | Tandem Diabetes Care, Inc. | Methods and devices for determination of flow reservoir volume |
US8573027B2 (en) | 2009-02-27 | 2013-11-05 | Tandem Diabetes Care, Inc. | Methods and devices for determination of flow reservoir volume |
WO2011014704A2 (en) | 2009-07-30 | 2011-02-03 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
CN102625807B (zh) | 2009-09-08 | 2016-03-09 | 霍夫曼-拉罗奇有限公司 | 4-取代的吡啶-3-基-甲酰胺化合物和使用方法 |
CN102791715B (zh) | 2009-12-31 | 2016-04-27 | 卡洛斯三世国家癌症研究中心基金会 | 用作激酶抑制剂的三环化合物 |
US9073927B2 (en) | 2010-01-22 | 2015-07-07 | Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii | Inhibitors of PI3 kinase |
EP2536720A1 (en) | 2010-02-18 | 2012-12-26 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Triazolo [4, 5 - b]pyridin derivatives |
WO2011121317A1 (en) | 2010-04-01 | 2011-10-06 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors |
WO2012052745A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
CN102649773A (zh) * | 2011-02-23 | 2012-08-29 | 苏州波锐生物医药科技有限公司 | 氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途 |
KR20140022053A (ko) | 2011-04-01 | 2014-02-21 | 제넨테크, 인크. | Akt 및 mek 억제제 화합물의 조합물, 및 사용 방법 |
SG194045A1 (en) | 2011-04-01 | 2013-11-29 | Genentech Inc | Combinations of akt inhibitor compounds and abiraterone, and methods of use |
EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
KR101953210B1 (ko) | 2011-05-19 | 2019-02-28 | 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ | 단백질 키나아제 억제제로서의 대환식 화합물 |
WO2013005041A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Tricyclic heterocyclic compounds as kinase inhibitors |
WO2013004984A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Tricyclic compounds for use as kinase inhibitors |
WO2013005057A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | New compounds |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
CN103570594A (zh) * | 2012-08-01 | 2014-02-12 | 苏州迈泰生物技术有限公司 | 二芳基胺类化合物及其在制备抗恶性肿瘤药物中的用途 |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
US11066358B1 (en) | 2021-02-17 | 2021-07-20 | Warner-Lambert Company Llc | Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
US11084780B1 (en) | 2021-02-17 | 2021-08-10 | Springworks Therapeutics, Inc. | Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
AU2021428932A1 (en) | 2021-02-17 | 2023-09-21 | Warner-Lambert Company Llc | Compositions of essentially pure form iv of n-((r)-2,3- dihydroxypropoxy)-3,4-difluoro-2- (2-fluoro-4-iodophenylamino)- benzamide and uses thereof |
JP2024507213A (ja) | 2021-02-17 | 2024-02-16 | スプリングワークス、セラピューティクス、インコーポレイテッド | N-((r)-2,3-ジヒドロキシプロポキシ)-3,4-ジフルオロ-2-(2-フルオロ-4-ヨード-フェニルアミノ)-ベンズアミドの分散性製剤及びその使用 |
US11571402B2 (en) | 2021-02-17 | 2023-02-07 | Springworks Therapeutics, Inc. | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
CN117083264A (zh) | 2021-02-17 | 2023-11-17 | 斯普林渥克斯治疗股份有限公司 | Mek抑制剂n-((r)-2,3-二羟基丙氧基)-3,4-二氟-2-(2-氟-4-碘-苯基氨基)-苯甲酰胺的结晶固体及其用途 |
US20230293463A1 (en) | 2022-03-17 | 2023-09-21 | SpringWorks Therapeutics Inc. | Treatment of cutaneous neurofibromas with Mirdametinib |
WO2023178266A2 (en) * | 2022-03-17 | 2023-09-21 | SpringWorks Therapeutics Inc. | Fluorinated phenylamino compounds and pharmaceutical compositions |
WO2023223205A1 (en) | 2022-05-17 | 2023-11-23 | Teva Pharmaceuticals International Gmbh | Solid state forms of mirdametinib and process for preparation thereof |
US20240307327A1 (en) | 2023-03-16 | 2024-09-19 | Springworks Therapeutics, Inc. | Dosage forms of mirdametinib |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5155110A (en) | 1987-10-27 | 1992-10-13 | Warner-Lambert Company | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition |
US6251943B1 (en) | 1997-02-28 | 2001-06-26 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a MEK inhibitor |
CN1163475C (zh) | 1997-07-01 | 2004-08-25 | 沃尼尔·朗伯公司 | 4-溴或4-碘苯基氨基苯氧肟酸衍生物及其作为mek抑制剂的用途 |
ES2274572T3 (es) | 1997-07-01 | 2007-05-16 | Warner-Lambert Company Llc | Derivados de acido 2-(4-bromo- o 4-yodo-fenilamino) benzoico y su uso como inhibidor de mek. |
GB9726851D0 (en) | 1997-12-19 | 1998-02-18 | Zeneca Ltd | Human signal transduction serine/threonine kinase |
AU1951499A (en) | 1998-01-06 | 1999-07-26 | General Hospital Corporation, The | Use of mek1 inhibitors as protective agents against damage due to ischemia |
EP1133467B1 (en) | 1998-12-04 | 2004-09-15 | Neurosearch A/S | Ion channel modulating agents |
IL143231A0 (en) | 1998-12-15 | 2002-04-21 | Warner Lambert Co | Use of a mek inhibitors for preventing transplant rejection |
IL143236A0 (en) | 1998-12-16 | 2002-04-21 | Warner Lambert Co | Treatment of arthritis with mek inhibitors |
SK8712001A3 (en) | 1998-12-22 | 2002-02-05 | Warner Lambert Co | Combination chemotherapy |
JP2002534380A (ja) | 1999-01-07 | 2002-10-15 | ワーナー−ランバート・カンパニー | Mek阻害剤による喘息の治療 |
AU2203800A (en) | 1999-01-07 | 2000-07-24 | Warner-Lambert Company | Antiviral method using mek inhibitors |
JP2001055376A (ja) | 1999-01-13 | 2001-02-27 | Warner Lambert Co | ジアリールアミン |
OA11819A (en) | 1999-01-13 | 2005-08-17 | Warner Lambert Co | 1-Heterocycle substituted diarylamines. |
BR9916857A (pt) | 1999-01-13 | 2001-12-04 | Warner Lambert Co | 4 heteroaril diarilaminas |
CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
CA2349832A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
EP1144385B1 (en) | 1999-01-13 | 2005-08-17 | Warner-Lambert Company Llc | Benzoheterocycles and their use as mek inhibitors |
US6455582B1 (en) | 1999-01-13 | 2002-09-24 | Warner-Lambert Company | Sulohydroxamic acids and sulohyroxamates and their use as MEK inhibitors |
KR20020012315A (ko) | 1999-07-16 | 2002-02-15 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Mek 저해제를 사용한 만성 통증의 치료 방법 |
AU5912500A (en) | 1999-07-16 | 2001-02-05 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
IL147617A0 (en) | 1999-07-16 | 2002-08-14 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
AU2735201A (en) | 1999-12-28 | 2001-07-09 | Pharmacopeia, Inc. | Pyrimidine and triazine kinase inhibitors |
MXPA02008103A (es) | 2000-03-15 | 2002-11-29 | Warner Lambert Co | Diarilaminas sustituidas con 5-amida como inhibidores mek. |
DE10017480A1 (de) | 2000-04-07 | 2001-10-11 | Transmit Technologietransfer | Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren |
ES2461854T3 (es) * | 2000-07-19 | 2014-05-21 | Warner-Lambert Company Llc | Ésteres oxigenados de ácidos 4-yodofenilamino-benzhidroxámicos |
AU2001277044A1 (en) | 2000-08-25 | 2002-03-13 | Warner-Lambert Company Llc | Process for making N-aryl-anthranilic acids and their derivatives |
CZ2003636A3 (cs) * | 2000-09-08 | 2003-08-13 | Ono Pharmaceutical Co., Ltd. | Krystalické formy N-hydroxy-2(S)-methyl-5-ethoxymethoxy-4-(S)-[N-(4-fenoxyfenylkarbonyl)amino]pentanamidu, způsoby jejich přípravy a farmaceutické kompozice, které je obsahují jako účinnou přísadu |
US20040122058A1 (en) | 2001-03-06 | 2004-06-24 | Dorian Bevec | Use of specific compounds particularly kinase inhibitors for treating viral infections |
AU2002255852B2 (en) | 2001-03-22 | 2006-11-09 | Van Andel Research Institute | Anthrax lethal factor inhibits tumor growth and angiogenesis |
NZ518726A (en) * | 2001-05-09 | 2004-06-25 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
WO2003054180A1 (en) * | 2001-12-21 | 2003-07-03 | Warner-Lambert Company Llc | Modified mek1 and mek2, crystal of a peptide: ligand: cofactor complex containing such modified mek1 or mek2, and methods of use thereof |
JP2005515253A (ja) | 2002-01-23 | 2005-05-26 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | N−(4−置換フェニル)−アントラニル酸ヒドロキサメートエステル |
DOP2003000556A (es) | 2002-01-23 | 2003-10-31 | Warner Lambert Co | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico. |
MXPA05003431A (es) * | 2002-11-15 | 2005-07-05 | Warner Lambert Co | Quimioterapia de combinacion. |
-
2004
- 2004-10-11 BR BRPI0415710-9A patent/BRPI0415710A/pt not_active IP Right Cessation
- 2004-10-11 JP JP2006536192A patent/JP2007509125A/ja active Pending
- 2004-10-11 NZ NZ546011A patent/NZ546011A/en unknown
- 2004-10-11 CA CA002542210A patent/CA2542210A1/en not_active Abandoned
- 2004-10-11 EP EP04769603A patent/EP1682495A1/en not_active Withdrawn
- 2004-10-11 CN CN200480030534A patent/CN100594212C/zh not_active Expired - Fee Related
- 2004-10-11 MX MXPA06004363A patent/MXPA06004363A/es unknown
- 2004-10-11 AU AU2004283148A patent/AU2004283148A1/en not_active Abandoned
- 2004-10-11 WO PCT/IB2004/003309 patent/WO2005040098A1/en active Application Filing
- 2004-10-11 RU RU2006113437/04A patent/RU2352558C2/ru not_active IP Right Cessation
- 2004-10-11 KR KR1020067007613A patent/KR101013932B1/ko not_active IP Right Cessation
- 2004-10-19 AR ARP040103782A patent/AR046124A1/es not_active Application Discontinuation
- 2004-10-20 US US10/969,681 patent/US7060856B2/en not_active Expired - Fee Related
- 2004-10-20 TW TW093131810A patent/TW200524584A/zh unknown
-
2006
- 2006-03-16 IL IL174367A patent/IL174367A0/en unknown
- 2006-03-17 ZA ZA200602250A patent/ZA200602250B/en unknown
- 2006-04-20 CO CO06037639A patent/CO5690569A2/es not_active Application Discontinuation
- 2006-05-09 NO NO20062090A patent/NO20062090L/no not_active Application Discontinuation
-
2007
- 2007-01-03 HK HK07100071.5A patent/HK1093483A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ZA200602250B (en) | 2007-05-30 |
WO2005040098A1 (en) | 2005-05-06 |
US7060856B2 (en) | 2006-06-13 |
AU2004283148A1 (en) | 2005-05-06 |
KR101013932B1 (ko) | 2011-02-14 |
TW200524584A (en) | 2005-08-01 |
MXPA06004363A (es) | 2006-06-14 |
JP2007509125A (ja) | 2007-04-12 |
IL174367A0 (en) | 2006-08-01 |
NZ546011A (en) | 2009-09-25 |
CA2542210A1 (en) | 2005-05-06 |
NO20062090L (no) | 2006-07-12 |
RU2352558C2 (ru) | 2009-04-20 |
US20050085550A1 (en) | 2005-04-21 |
BRPI0415710A (pt) | 2006-12-19 |
EP1682495A1 (en) | 2006-07-26 |
HK1093483A1 (en) | 2007-03-02 |
KR20060080230A (ko) | 2006-07-07 |
CO5690569A2 (es) | 2006-10-31 |
CN1867543A (zh) | 2006-11-22 |
CN100594212C (zh) | 2010-03-17 |
RU2006113437A (ru) | 2006-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR046124A1 (es) | Forma polimorfica de la n-[(r)-2,3-dihidroxipropoxi]-3,4 difluoro-2-(2-fluoro-4-iodofenilamino)benzamida; proceso de obtencion y composiciones farmaceuticas | |
AR077416A2 (es) | Compuesto polimorfo estable de flibanserina , procedimiento industrial para su preparacion y uso del mismo para preparar medicamentos | |
AR050374A1 (es) | Forma polimorfica de rafampicina | |
HRP20161581T1 (hr) | DEUTERIRANI d9-VENLAFAKSI | |
ECSP095220A (es) | Derivados de n-fenil-2-pirimidin-amina | |
WO2007015004A3 (fr) | Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent | |
WO2007015002A3 (fr) | Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent | |
WO2007015003A3 (fr) | Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent | |
EA200300103A1 (ru) | НОВАЯ β КРИСТАЛЛИЧЕСКАЯ ФОРМА ТРЕТ-БУТИЛАМИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ЕЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ | |
AR048235A1 (es) | Un procedimiento para la sintesis de (7-metoxi-3,4-dihidro-1-naftalenil)acetonitrilo y su aplicacion en la sintesis de agomelatina | |
CO6410293A2 (es) | Nueva formula cristalina vi de la agomelatina preparación y uso de la misma | |
RS51079B (sr) | Novi naftalenski derivati, postupak njihove proizvodnje i farmaceutske smeše koje ih sadrže | |
BR0313150A (pt) | Cápsulas de gelatina que exibem ligação reticulada reduzida | |
BR0115616A (pt) | Preparação de inibidores de permutadores sódio-hidrogênio do tipo 1 | |
BR0307708A (pt) | Compostos tricìclicos de n-acila | |
TH18295S1 (th) | อุปกรณ์สร้างภาพ | |
TH18291S1 (th) | อุปกรณ์สร้างภาพ | |
TH63453S (th) | อุปกรณ์สร้างภาพ | |
TH63452S (th) | อุปกรณ์สร้างภาพ | |
TH63461S (th) | อุปกรณ์สร้างภาพ | |
TH19133S1 (th) | อุปกรณ์สร้างภาพ | |
TH63455S (th) | อุปกรณ์สร้างภาพ | |
TH63459S (th) | อุปกรณ์สร้างภาพ | |
TH63454S (th) | อุปกรณ์สร้างภาพ | |
TH63460S (th) | อุปกรณ์สร้างภาพ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |